OTCPK:BNKL

Stock Analysis Report

Executive Summary

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • Bionik Laboratories has significant price volatility in the past 3 months.
  • Bionik Laboratories is not covered by any analysts.

Similar Companies

Share Price & News

How has Bionik Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.5%

OTCPK:BNKL

1.2%

US Medical Equipment

0.9%

US Market


1 Year Return

-52.6%

OTCPK:BNKL

14.7%

US Medical Equipment

0.3%

US Market

BNKL underperformed the Medical Equipment industry which returned 14.5% over the past year.

BNKL underperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

BNKLIndustryMarket
7 Day-4.5%1.2%0.9%
30 Day0.3%0.9%-1.9%
90 Day-20.0%10.9%1.6%
1 Year-52.6%-52.6%15.6%14.7%2.6%0.3%
3 Year-97.6%-97.6%68.0%62.8%41.0%31.8%
5 Yearn/a132.7%105.9%55.2%38.0%

Price Volatility Vs. Market

How volatile is Bionik Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bionik Laboratories undervalued based on future cash flows and its price relative to the stock market?

0.48x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Bionik Laboratories to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Bionik Laboratories to establish if it is available at substantial discount.


Price Based on Earnings

Bionik Laboratories is loss making, we can't compare its value to the US Medical Equipment industry average.

Bionik Laboratories is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Bionik Laboratories, we can't assess if its growth is good value.


Price Based on Value of Assets

Bionik Laboratories is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Bionik Laboratories expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bionik Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of BNKL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Bionik Laboratories's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Bionik Laboratories performed over the past 5 years?

-19.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Bionik Laboratories does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Bionik Laboratories's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Bionik Laboratories's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Bionik Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Bionik Laboratories has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Bionik Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Bionik Laboratories's financial position?


Financial Position Analysis

Bionik Laboratories's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Bionik Laboratories's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Bionik Laboratories's level of debt (5.7%) compared to net worth is satisfactory (less than 40%).

Bionik Laboratories had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Bionik Laboratories has less than a year of cash runway based on current free cash flow.

Bionik Laboratories has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.7% each year.


Next Steps

Dividend

What is Bionik Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Bionik Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Bionik Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Bionik Laboratories has not reported any payouts.

Unable to verify if Bionik Laboratories's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Bionik Laboratories has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Bionik Laboratories's salary, the management and board of directors tenure and is there insider trading?

2.4yrs

Average management tenure


CEO

Eric Dusseux (51yo)

1.9yrs

Tenure

US$1,031,769

Compensation

Dr. Eric Michel Dusseux, MD, MSc, MBA, has been Director of MC10, Inc. since June 2019. Dr Dusseux has been the Chief Executive Officer at Bionik Laboratories Corp. since September 1, 2017. Dr. Dusseux was ...


CEO Compensation Analysis

Eric's remuneration is higher than average for companies of similar size in United States of America.

Eric's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.4yrs

Average Tenure

51yo

Average Age

The tenure for the Bionik Laboratories management team is about average.


Board Age and Tenure

1.4yrs

Average Tenure

62.5yo

Average Age

The average tenure for the Bionik Laboratories board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Leslie Markow (59yo)

    Chief Financial Officer

    • Tenure: 4.9yrs
    • Compensation: US$252.47k
  • Isador Lieberman

    Medical Director and Clinical Advisor

    • Tenure: 0.0yrs
  • Michal Prywata (28yo)

    Co-Founder

    • Tenure: 0.4yrs
    • Compensation: US$233.44k
  • Bill Harris

    Marketing Director

    • Tenure: 2.4yrs
  • Eric Dusseux (51yo)

    CEO & Director

    • Tenure: 1.9yrs
    • Compensation: US$1.03m

Board Members

  • Joe Martin (71yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: US$50.00k
  • Gary Henley (70yo)

    • Tenure: 0.0yrs
  • Isador Lieberman

    Medical Director and Clinical Advisor

    • Tenure: 0.0yrs
  • Peter Malone (68yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: US$50.00k
  • Michal Prywata (28yo)

    Co-Founder

    • Tenure: 0.4yrs
    • Compensation: US$233.44k
  • Kaamran Raahemifar

    Control Systems and Electronics Advisor

    • Tenure: 0.0yrs
  • Edward Lemaire

    Clinical Trial Advisor & Investigator

    • Tenure: 0.0yrs
  • Dany Gagnon

    Clinical Trial Advisor & Investigator

    • Tenure: 0.0yrs
  • Eric Dusseux (51yo)

    CEO & Director

    • Tenure: 1.9yrs
    • Compensation: US$1.03m
  • André-Jacques Auberton-Hervé (57yo)

    Chairman of the Board

    • Tenure: 1.6yrs
    • Compensation: US$180.00k

Company Information

Bionik Laboratories Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bionik Laboratories Corp.
  • Ticker: BNKL
  • Exchange: OTCPK
  • Founded: 2010
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$12.348m
  • Shares outstanding: 3.86m
  • Website: https://www.bioniklabs.com

Number of Employees


Location

  • Bionik Laboratories Corp.
  • 483 Bay Street
  • Office N105
  • Toronto
  • Ontario
  • M5G 2C9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BNKLOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2015

Biography

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion ARM ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 00:26
End of Day Share Price2019/08/15 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.